← Back to results
NCT05999084RECRUITING

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

Georgia Memory Net Center for Medicare and Medicaid Services Registry for Anti-Amyloid Monoclonal Antibody Coverage With Evidence Development

Sponsor: Emory University + Centers for Medicare and Medicaid Services

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Request endpoint coverage

Key Facts

Study type
OBSERVATIONAL
Conditions
Alzheimer Disease
Interventions
Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care
Enrollment
735 participants
Primary completion
Jul 2028
Study completion
Jul 2028
First posted
Aug 2023
Last updated
Mar 2026

Primary Endpoints (CT.gov)

Change in Quick Dementia Rating System (QDRS) Score

Time frame: Baseline and every 6 months until end of study (up to 5 years)

Montreal Cognitive Assessment (MoCA) Score

Time frame: Baseline and every 6 months until end of study (up to 5 years)

Change in Functional Activities Questionnaire (FAQ) Score

Time frame: Baseline and every 6 months until end of study (up to 5 years)

Change in Lawton-Brody Activities of Daily Living (ADL) Physical Self-Maintenance Scale (PSMS) Score

Time frame: Baseline and every 6 months until end of study (up to 5 years)

Secondary Endpoints

Change in Care Needs Assessment Tool (CNAT) Score

Change in Zarit Burden Interview Score

Change in Patient-Reported Outcomes Measurement Information System Global Health (PROMIS 10) Score

Eligibility Criteria

Inclusion Criteria: 1. Age 50-90, inclusive 2. Diagnosis: Mild Cognitive Impairment (MCI) or mild AD dementia with positive cerebrospinal fluid (CSF) or amyloid PET 3. Objective measurement of baseline cognition and function within past 3 months: * Cognitive: Mini-Mental State Examination (MMSE) ≥ 22, MoCA ≥ 16 * Function: Independence in basic ADLs * Function: FAQ ≤ 9 may justify inclusion with lower cognitive score if felt to be impacted by prominent language impairment or other factors affecting score 4. MRI brain within last year and no exclusionary criteria 5. Complete blood count (CBC), comprehensive metabolic panel (CMP), B12, thyroid stimulating hormone (TSH), prothrombin time (PT), partial thromboplastin time (PTT), and International Normalized Ratio (INR) without clinically significant abnormality 6. Informant/care partner/family available to attend follow-up visits to provide information regarding patient's cognitive and functional abilities 7. Agree to MRI, PET,

Read full criteria on CT.gov →

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Request coverage →

Source

Open on ClinicalTrials.gov